VWF propeptide in defining VWD subtypes

Sandra L Haberichter1

  • 1BLOODCENTER OF WISCONSIN.

Blood
|May 9, 2015
PubMed

Insights

This study clarifies the pathophysiology of von Willebrand disease (VWD) types 1, 2, and 3 using specific biomarker ratios. Researchers analyzed von Willebrand factor propeptide (VWFpp) and factor VIII activity relative to VWF antigen levels.

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • Von Willebrand disease (VWD) is a heterogeneous bleeding disorder.
  • Accurate classification of VWD subtypes is crucial for effective management.
  • Previous diagnostic methods have limitations in differentiating VWD types.

Purpose of the Study:

  • To elucidate the pathophysiology of VWD types 1, 2, and 3.
  • To evaluate the utility of VWFpp and FVIII:VWFag ratios in classifying VWD.
  • To provide a more precise diagnostic approach for VWD.

Main Methods:

  • Analysis of data from the Willebrand in the Netherlands (WiN) study.
  • Measurement of von Willebrand factor propeptide (VWFpp) levels.
  • Assessment of factor VIII activity (FVIII) and VWF antigen (VWFag) levels.
  • Calculation and comparison of VWFpp/VWFag and FVIII/VWFag ratios across VWD types.

Main Results:

  • Distinct patterns in VWFpp/VWFag and FVIII/VWFag ratios were observed for VWD types 1, 2, and 3.
  • These ratios effectively differentiated between the major VWD subtypes.
  • The findings support the use of these ratios as diagnostic biomarkers.

Conclusions:

  • The study successfully defined the pathophysiological basis of VWD types 1, 2, and 3 using biomarker ratios.
  • VWFpp/VWFag and FVIII/VWFag ratios offer a valuable tool for VWD classification.
  • This research contributes to improved diagnosis and understanding of VWD.

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.9K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
6.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.7K